A bankrupt proton center is a financing failure, not a clinical one.
Nearly a third of U.S. proton therapy centers have defaulted, restructured, or filed for bankruptcy. The cause is almost never clinical. It is the gap between $500M+ in municipal bond debt and $40M of operating revenue at a standalone center cut off from the referral pipelines it needs to survive.
This white paper lays out the thesis that defines the next generation of proton therapy ownership. Decoupled from its original capital structure, a bankrupt proton center becomes a highly viable clinical asset for a dominant regional provider, paired with a specialized medical real estate investor that takes the building onto its own balance sheet and leases it back NNN.
"The failure of a proton center is almost never a failure of the clinical model. It is a failure of the financing model. Reset the basis, and the asset works."
Eleven sections, two anchor case studies.
- 01
The origins of proton therapy financial distress.
Why municipal bond debt, volume projections, and standalone operating costs combined to break the first generation of centers.
- 02
Why proton centers become compelling acquisition targets in bankruptcy.
The cost gap between $260–350M ground-up development and $15–110M distressed acquisitions, with a side-by-side breakdown.
- 03
The strategic role of the regional oncology practice.
How an existing patient pipeline, payer relationships, and a CMD-led prior-auth team neutralize the failure mode of standalone operators.
- 04
The strategic role of the real estate partner.
Why a mission-critical, purpose-built proton facility is the ideal NNN tenant for a specialized healthcare REIT.
- 05
Lease structure and regulatory architecture.
Term, escalators, fixturization, change of control, TI allowances, and Stark / Anti-Kickback fair-market-value compliance.
- 06
Financial benefits for the real estate investor.
Cap rate spreads against Class A MOBs, downside protection from replacement cost, and lease tenor.
- 07
Dual-track due diligence.
The clinical and operational checklist for the practice paired with the asset-level checklist for the investor.
- 08
Service mix and throughput strategy.
Which tumor sites and modalities drive the post-turnaround volume model, and how to phase them in.
- 09
Risk factors and mitigation.
Volume ramp, payer behavior, staffing scarcity, technology obsolescence, and how to underwrite them.
- 10
Anchor case studies.
Knoxville (Covenant Health / Provision CARES) and Nashville (Tennessee Oncology / Montecito) as the two halves of the structure.
- 11
Strategic lessons and final observations.
What the data says about price ranges, CON transferability, and the operating cadence that separates winning bids from failed ones.
Knoxville and Nashville: a 363 sale and a leaseback, executed.
The full paper walks through the Covenant Health acquisition of Provision CARES at $45.25M, roughly half of replacement cost, and the Tennessee Oncology / Montecito leaseback in Franklin. Together they show both halves of the structure the paper recommends.
$45.25M
Knoxville price
~50%
Discount to replacement
§363
Free-and-clear sale